BioMark Diagnostics Inc
Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic platform to detect, monitor, and treat cancer. The company invests in and develops liquid biopsy metabolic panel assay for early stage diagnosis of lung cancer. It has a strategic partnership with Rubix LS to develop diagnostic tools to enhance lung cancer screening and improve breast cancer screening program for wo… Read more
Market Cap & Net Worth: BioMark Diagnostics Inc (BMKDF)
BioMark Diagnostics Inc (PINK:BMKDF) has a market capitalization of $16.45 Million ($16.45 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #29289 globally and #9713 in its home market, demonstrating a 2.84% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioMark Diagnostics Inc's stock price $0.18 by its total outstanding shares 90886200 (90.89 Million).
BioMark Diagnostics Inc Market Cap History: 2015 to 2025
BioMark Diagnostics Inc's market capitalization history from 2015 to 2025. Data shows growth from $10.00 Million to $16.45 Million (8.77% CAGR).
BioMark Diagnostics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioMark Diagnostics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
86.53x
BioMark Diagnostics Inc's market cap is 86.53 times its annual revenue
0.69x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $11.07 Million | $263.28K | -$1.22 Million | 42.05x | N/A |
| 2022 | $13.49 Million | $43.93K | -$1.45 Million | 307.00x | N/A |
| 2023 | $16.36 Million | $153.49K | -$1.84 Million | 106.58x | N/A |
| 2024 | $14.12 Million | $163.22K | -$1.43 Million | 86.53x | N/A |
Competitor Companies of BMKDF by Market Capitalization
Companies near BioMark Diagnostics Inc in the global market cap rankings as of March 18, 2026.
Key companies related to BioMark Diagnostics Inc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
BioMark Diagnostics Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, BioMark Diagnostics Inc's market cap moved from $10.00 Million to $ 16.45 Million, with a yearly change of 8.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $16.45 Million | +16.47% |
| 2024 | $14.12 Million | -13.67% |
| 2023 | $16.36 Million | +21.29% |
| 2022 | $13.49 Million | -21.81% |
| 2021 | $17.25 Million | +55.83% |
| 2020 | $11.07 Million | -21.52% |
| 2019 | $14.11 Million | +269.52% |
| 2018 | $3.82 Million | -51.95% |
| 2017 | $7.94 Million | -7.02% |
| 2016 | $8.54 Million | -14.55% |
| 2015 | $10.00 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of BioMark Diagnostics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $16.45 Million USD |
| MoneyControl | $16.45 Million USD |
| MarketWatch | $16.45 Million USD |
| marketcap.company | $16.45 Million USD |
| Reuters | $16.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.